Table 3.

Pons V_T, K₁, and k₂ of [¹¹C]flumazenil before and after tariquidar administration derived using the 1TC model.

	VT			K1 (mL · cm−3 · min−1)			k2 (min−1)
Patient	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a
1	0.87	1.01	17	0.31	0.38	21	0.36	0.38	4
2	0.86	0.97	13	0.25	0.27	7	0.29	0.28	−5
3	0.77	0.91	18	0.27	0.33	22	0.35	0.36	3
4	0.82	1.03	25	0.26	0.30	14	0.32	0.29	−9
5	0.80	0.97	22	0.32	0.31	−4	0.40	0.32	−21
6	0.95	1.17	23	0.39	0.33	−15	0.41	0.28	−31
7	0.79	0.92	15	0.21	0.22	5	0.27	0.25	−9
8	1.10	1.08	−2	0.37	0.35	−7	0.34	0.32	−5
9	0.95	1.14	20	0.28	0.26	−7	0.30	0.23	−23
AVG	0.88	1.02	17	0.30	0.31	4	0.34	0.30	−11
SD	0.10	0.09	8	0.06	0.05	13	0.05	0.05	12

V_T: distribution volume; K₁: influx rate constant (mL · cm⁻³ · min⁻¹); k₂: efflux rate constant (min⁻¹); 1TC model: 1 tissue compartment model, TQD: tariquidar; AVG: average; SD: standard deviation.

^aPercentage change after tariquidar administration relative to baseline.